培美曲塞联合替吉奥治疗复发转移性乳腺癌的临床效果

Clinical effect of Pemetrexed combined with Tegafur Gimeracil Otera in the treatment of recurrent metastatic breast cancer

目的观察分析培美曲塞联合替吉奥治疗复发转移性乳腺癌的临床效果和不良反应。方法选取我院2015年8月~2016年8月收治的56例复发转移性乳腺癌患者作为研究对象,随机分为对照组和观察组,每组28例。观察组采用培美曲塞联合替吉奥治疗,每3周为1个治疗周期,对照组采用替吉奥治疗。所有患者至少接受2个周期以上的化疗,观察两组的疗效和不良反应。结果观察组的生存率为75.00%,复发率为3.57%,均优于对照组的35.71%、39.29%,差异有统计学意义(P<0.05)。观察组和对照组的病死率比较,差异无统计学意义(P>0.05)。观察组的消化道反应发生率为32.14%,血液学毒性发生率为46.43%,肝功能毒性发生率为32.14%,均低于对照组的57.14%、72.43%、25.00%,差异有统计学意义(P<0.05)。观察组的神经毒性发生率、肝功能毒性反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论培美曲塞联合替吉奥治疗复发转移性乳腺癌具有显著疗效,不良反应发生率低,可耐受,值得临床推广研究。

Objective To observe and analyze the clinical efficacy and adverse reactions of Pemetrexed combined with Tegafur Gimeracil Otera in the treatment of recurrent metastatic breast cancer.Methods From August 2015 to August 2016,56 patients with recurrent metastatic breast cancer in our hospital were selected and randomly divided into the control group and the observation group,28 cases in each group.In the observation group,Pemetrexed combined with Tegafur Gimeracil Otera was adopted,every 3 weeks was considered as a treatment cycle.In the control group,only Tegafur Gimeracil Otera was used,every participant should be treated for at least two cycles,and effect and adverse reactions were evaluated between the two groups.Results In the observation group,the survival rate and recurrence rate were 75.00% and 3.57% respectively,which were both superior to those in the control group （35.71%,39.29%）,with significant difference （P〈0.05）.There was no significant difference between the two groups in mortality （P〉0.05）.The incidence of digestive tract reaction in the observation group was 32.14%,the incidence rate of hematologic toxicity was 46.43%,and the incidence of liver function toxicity was 32.14%,which were lower than those in the control group （57.14%,72.43%,25.00%）,with significant difference （P〈0.05）.There was no significant difference in the incidence of neurotoxicity and liver function toxic reaction between the two groups （P〉0.05）.Conclusion Combination of Pemetrexed and Tegafur Gimeracil Otera can obtain a remarkable effect on treating recurrent metastatic breast cancer in a low adverse reactions.h can be tolerated and is worthy of clinical promotion and research.